Trials / Completed
CompletedNCT01039428
A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- KDL Inc. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This was a study to evaluate the efficacy and safety of HS219, chitosan-loaded chewing gum, when given three times a day for 3 weeks to the hemodialysis (HD) patients with hyperphosphatemia whose serum inorganic phosphorus was not well controlled with calcium carbonate or sevelamer hydrogen chloride.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | HS219 | Chewing for 30 min three time a day far after meal |
| DIETARY_SUPPLEMENT | Placebo | Chewing for 30 min three times a day far after meal |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2010-05-01
- Completion
- 2010-06-01
- First posted
- 2009-12-25
- Last updated
- 2015-09-14
- Results posted
- 2012-06-01
Locations
11 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01039428. Inclusion in this directory is not an endorsement.